Nemdx and collaborators reported a blood-based functional assay for TDP-43 evaluated across 1,080 human samples. The work provides substantial human validation of the Nemdx molecular-design platform.https://www.mdpi.com/2079-6374/16/8/446
Biosensors, 2026 – TDP-43 functional activity Read More »
Nemdx presented initial work combining TDP-43 functional activity, NfL and total tau in a multi-component serum biomarker framework. The exploratory analysis supports the rationale for measuring complementary aspects of neurodegenerative disease biology.
Target ALS, 2025: Multi-component functional profiling Read More »
Boston, MA., Oct. 21, 2024 /PRNewswire/ — Nemdx, Inc. today announced a poster presentation at the 2024 Northeast ALS Annual Conference (NEALS) hosted online on October 21-24. The poster, presented by Vito Levi D’Ancona, president of Nemdx, will feature amyotrophic lateral sclerosis (ALS) research, including findings from testing over 300 samples from multiple biorepositories provided
NEALS, 2024: TDP-43 function versus quantification: BASIC SCIENCE AWARD Read More »
Boston- ALS Finding a Cure® (ALSFAC) has awarded a $400,000 grant to a team of researchers from Massachusetts General Hospital (MGH), a Boston based private entity Nemdx Inc. (Nemdx), and the International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy, for their project “Developing a Comprehensive Blood Test for Sporadic and Familial ALS.” Dr.
ALS Finding a Cure (ALSFAC) has awarded a $400,000 grant to Nemdx Inc. (Nemdx) Read More »